Xenon CMO Christopher John Kenney reports disposal of common shares worth $425,469.33
XENE•Kenney discloses share sale
- Xenon Pharmaceuticals Chief Medical Officer Christopher John Kenney sold 7,068 common shares on Aug. 28, 2026.
- Shares sold at weighted-average prices of $60.17, $60.98.
- Kenney’s direct holding fell to 2 common shares.
